Schwab Charles Investment Management Inc. lifted its holdings in shares of MacroGenics Inc (NASDAQ:MGNX) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 175,106 shares of the biopharmaceutical company’s stock after buying an additional 6,118 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 0.48% of MacroGenics worth $3,328,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the company. The Manufacturers Life Insurance Company raised its stake in shares of MacroGenics by 2.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,485 shares of the biopharmaceutical company’s stock worth $463,000 after buying an additional 743 shares during the period. Wells Fargo & Company MN raised its stake in shares of MacroGenics by 11.5% during the 3rd quarter. Wells Fargo & Company MN now owns 27,714 shares of the biopharmaceutical company’s stock worth $513,000 after buying an additional 2,862 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of MacroGenics by 19.3% during the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 31,210 shares of the biopharmaceutical company’s stock worth $577,000 after buying an additional 5,050 shares during the period. Cornerstone Capital Management Holdings LLC. raised its stake in shares of MacroGenics by 43.9% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 33,438 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 10,200 shares during the period. Finally, Parametric Portfolio Associates LLC acquired a new position in shares of MacroGenics during the 2nd quarter worth approximately $203,000. 91.13% of the stock is owned by institutional investors and hedge funds.
Shares of MacroGenics Inc (NASDAQ:MGNX) opened at $29.19 on Tuesday. MacroGenics Inc has a 12-month low of $14.36 and a 12-month high of $32.74.
Several research analysts have recently weighed in on the company. BidaskClub raised MacroGenics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 13th. Zacks Investment Research upgraded MacroGenics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Cowen reiterated a “buy” rating on shares of MacroGenics in a research report on Wednesday, January 24th. ValuEngine upgraded MacroGenics from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $26.00 price target (up from $18.00) on shares of MacroGenics in a research report on Wednesday, March 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. MacroGenics has a consensus rating of “Buy” and an average price target of $29.78.
In related news, SVP Eric Blasius Risser sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $22.50, for a total transaction of $67,500.00. Following the completion of the sale, the senior vice president now directly owns 12,100 shares in the company, valued at $272,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jon Marc Wigginton sold 5,000 shares of the company’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. The disclosure for this sale can be found here. Insiders have sold 42,967 shares of company stock valued at $1,098,005 over the last quarter. 8.30% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://ledgergazette.com/2018/03/20/macrogenics-inc-mgnx-shares-bought-by-schwab-charles-investment-management-inc.html.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics Inc (NASDAQ:MGNX).
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.